Advertisement
New Zealand markets close in 3 hours 19 minutes

  • NZX 50

    11,864.67
    +61.39 (+0.52%)
     

  • NZD/USD

    0.5947
    +0.0013 (+0.21%)
     

  • NZD/EUR

    0.5546
    +0.0005 (+0.09%)
     

  • ALL ORDS

    7,978.30
    +40.40 (+0.51%)
     

  • ASX 200

    7,723.80
    +40.30 (+0.52%)
     

  • OIL

    83.29
    -0.07 (-0.08%)
     

  • GOLD

    2,333.30
    -8.80 (-0.38%)
     

  • NASDAQ

    17,471.47
    +260.59 (+1.51%)
     

  • FTSE

    8,044.81
    +20.94 (+0.26%)
     

  • Dow Jones

    38,503.69
    +263.71 (+0.69%)
     

  • DAX

    18,137.65
    +276.85 (+1.55%)
     

  • Hang Seng

    16,993.17
    +164.24 (+0.98%)
     

  • NIKKEI 225

    38,313.35
    +761.19 (+2.03%)
     

  • NZD/JPY

    91.8970
    +0.1310 (+0.14%)
     

Amarin’s Revenue Projections for 2018

Margaret Patrick
Updated
Amarin’s Revenue Projections for 2018

In the third-quarter earnings conference call, Amarin (AMRN) didn’t provide any revenue guidance for the fourth quarter, 2018, or 2019. After the REDUCE-IT trial results, Amarin aims to increase the number of sales representatives in the US market to 400 by the beginning of 2019. According to Amarin’s third-quarter earnings conference call, the expanded sales force and primary results published in the American Heart Association presentation on November 10 are expected to drive Vascepa’s revenue growth in future quarters.

Continue reading